02 Aug Graftys Renews Long-term Agreement with Arthrex
Liege (Belgium), August 1, 2022 – GRAFTYS SA (“Graftys”), is pleased to announce renewal of its multi-year supply agreement with Arthrex for advanced synthetic bone graft materials.
Aurelien Valet, Graftys’ Chief Executive Officer, says “We are proud that Arthrex has renewed its trust in Graftys through this long-term agreement which will provide multiple new business opportunities using state-of-the-art orthobiologic technology. Arthrex is one of the most successful and innovative companies in the orthopedic industry and we look forward to continuing our collaboration with them to address unmet clinical needs in sports medicine, orthopedic reconstruction, and trauma, on a global basis.” David Shepard, Senior Director, Orthobiologics and Vet Systems at Arthrex, added “We are pleased to renew our relationship with Graftys in support of our mission to help surgeons treat their patients better.”
Graftys is an innovation-driven medtech company committed to the development and manufacturing of synthetic bone biomaterials. Graftys’ products are registered in more than 25 countries worldwide, including Europe, USA, and South America. Graftys’ mission is to become a major player in the design, manufacturing, and distribution of bone biomaterials, thanks to a solid portfolio of products built on clinical evidence and addressing patient’s/surgeon’s medical needs, and thanks to an innovation-driven pipeline through partnerships with leading academic research institutions in Europe.
USA : Ron Lowell, Business Development +1 847 651 3723
SOURCE: Graftys, August 1 2022.
To find out more news from the industry head over to our news section – orthocg.com/news